Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG-641 with Nivolumab in Advanced Epithelial Tumours
NCT05043714Phase 1Completed
- Sponsor
- Akamis Bio
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of NG-641 in Epithelial tumor and squamous cell carcinoma of the head and neck (HNSCC), sponsored by Akamis Bio. Primary endpoint: Incidence of adverse events. Started Dec 2021; status: completed.
02
Drugs
NG-641
03
Conditions
Epithelial tumorsquamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05043714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043714.